Product Description
Arundic acid has been experimented in vitro and in vivo as a potential neuroprotective agent. It modulates astrocyte activation by inhibiting the enhanced astrocytic synthesis of S-100beta protein, responsible for inducing neuronal death. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/23514413/)
Mechanisms of Action: S-100β Synthesis Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Merck
Company Location: Eastern America
Company Founding Year: 1668
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Stroke
Phase 2: Ischemic Stroke|Infarction, Middle Cerebral Artery|Amyotrophic Lateral Sclerosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
JapicCTI-050098 |
JapicCTI-050098 | N/A |
Completed |
Ischemic Stroke |
None |
|||
2006-002660-26 |
2006-002660-26 | P2 |
Terminated |
Amyotrophic Lateral Sclerosis |
2009-07-08 |
2022-03-12 |
Treatments |
|
NCT00401310 |
NCT00401310 | P2 |
Terminated |
Infarction, Middle Cerebral Artery|Ischemic Stroke |
2009-01-01 |
2022-05-04 |
Primary Endpoints |
|
2008-002079-28 |
2008-002079-28 | P2 |
Terminated |
Ischemic Stroke |
2008-11-06 |
2025-05-25 |
Treatments |
|
2007-004723-37 |
2007-004723-37 | P2 |
Terminated |
Amyotrophic Lateral Sclerosis |
2008-09-03 |
2022-03-12 |
Treatments |
|
NCT00229177 |
ONO-2506-08 | P3 |
Completed |
Stroke |
2008-09-01 |
2019-03-21 |
Treatments |
|
NCT00046761 |
2506/INT0104 | P3 |
Terminated |
Stroke |
2005-05-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|